APS [210], when used as an adjuvant for oral Newcastle disease vaccination, was shown to increase lymphocyte proliferation and elevate the frequency of CD4+ and CD8+ T cells in peripheral blood and mucosal compartments. This evidence concerns the gene CD4 and Newcastle disease.